Skip to Main Content

Author Details

Amina Zoubeidi
University of British Columbia
2000
118
48
PMIDPaper TitleJournal TitlePublished Year
36718085Beyond Expression: Role of Phosphorylated Residues of EZH2 in Lineage Plasticity in Prostate Cancer.Endocrinology2023
37801613Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase.Cancer Res2023
37486978A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer.Mol Cancer Ther2023
37552603ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer.Cell Rep2023
37815914MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.Cell Rep2023
37470668The Transcriptional and Epigenetic Landscape of Cancer Cell Lineage Plasticity.Cancer Discov2023
34973338Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.J Biol Chem2022
35477723ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.Nat Commun2022
35754340Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.Cancer Discov2022
36251389The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.Cancer Res2022
33406413Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer.Cell Rep2021
33741908CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.Nat Commun2021
33542074Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.Clin Cancer Res2021
33785741Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.Nat Commun2021
33758253Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer.Sci Rep2021
34934057The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.Nat Commun2021
34737261Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.Nat Commun2021
34489572An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer.Nat Cell Biol2021
34625072Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.J Biomed Sci2021
34506104Development of a Benzothiazole Scaffold-Based Androgen Receptor N-Terminal Inhibitor for Treating Androgen-Responsive Prostate Cancer.ACS Chem Biol2021
34187942Celebrating the 80th anniversary of hormone ablation for prostate cancer.Endocr Relat Cancer2021
34128829Targeting androgen receptor signaling: a historical perspective.Endocr Relat Cancer2021
32802517Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells.Prostate Cancer2020
31845908Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models.J Clin Invest2020
31932422Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.Proc Natl Acad Sci U S A2020
31959826Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.Nat Commun2020
31804971The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.Endocr Relat Cancer2020
33187317Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer.Cancers (Basel)2020
30626088Development of a Transcriptional Amplification System Based on the PEG3 Promoter to Target Androgen Receptor-Positive and -Negative Prostate Cancer Cells.Int J Mol Sci2019
31900920Neural Transcription Factors in Disease Progression.Adv Exp Med Biol2019
31445843The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.Eur Urol2019
31363002The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.Clin Cancer Res2019
31013476PEG10 is associated with treatment-induced neuroendocrine prostate cancer.J Mol Endocrinol2019
30772358Biological Evolution of Castration-resistant Prostate Cancer.Eur Urol Focus2019
30655535ONECUT2 is a driver of neuroendocrine prostate cancer.Nat Commun2019
29348142SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.EMBO Mol Med2018
30033370Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30033362Risk SNP-Mediated Promoter-Enhancer Switching Drives Prostate Cancer through lncRNA PCAT19.Cell2018
30340047Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.Cell2018
30470788Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.Sci Rep2018
28315377Patient-derived xenografts: A platform for accelerating translational research in prostate cancer.Mol Cell Endocrinol2018
29572264Co-targeting driver pathways in prostate cancer: two birds with one stone.EMBO Mol Med2018
29544736Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.Eur Urol2018
29487201Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.Cancer Res2018
29460922Cellular plasticity and the neuroendocrine phenotype in prostate cancer.Nat Rev Urol2018
29757368The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.Gigascience2018
29258679Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.Eur Urol2018
27270433A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.Oncogene2017
28288135Targeting Lyn regulates Snail family shuttling and inhibits metastasis.Oncogene2017
29089623Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia.Sci Rep2017
  • 1 - 50 of 118

Recommended Authors

Joshua Urrutia
Knight Cancer Institute, Oregon Health & Science University (OHSU)
Career Start Year 2016
Number of shared co-authors 22
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 24
Alexandra Corella
Fred Hutchinson Cancer Research Center
Career Start Year 2015
Number of shared co-authors 9
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 12
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 23
Richard J Rebello
University of Melbourne
Career Start Year 2015
Number of shared co-authors 10
Yuliang Wang
The Chinese University of Hong Kong
Career Start Year 2014
Number of shared co-authors 3
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 24
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 36
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 8
Yu Chen
School of Pharmacy, University of Wisconsin-Madison
Career Start Year 2008
Number of shared co-authors 36
Alfonso Urbanucci
Northwestern University Feinberg School of Medicine Chicago
Career Start Year 2008
Number of shared co-authors 24
Dimple Chakravarty
Icahn School of Medicine at Mount Sinai
Career Start Year 2007
Number of shared co-authors 20
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 6
Christopher E Barbieri
Weill Cornell Medical College
Career Start Year 2003
Number of shared co-authors 35
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Career Start Year 2002
Number of shared co-authors 38
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 15
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 10
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 35
Nadia Boufaied
Research Institute of the McGill University Health Centre
Career Start Year 2000
Number of shared co-authors 24
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 49
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 12
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 31
Ian G Mills
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 27
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 44
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 38
Christopher M Hovens
Royal Melbourne Hospital, The University of Melbourne
Career Start Year 1989
Number of shared co-authors 13
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 37
Kenneth J Pienta
The Brady Urological Institute, Johns Hopkins University School of Medicine
Career Start Year 1981
Number of shared co-authors 52
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Career Start Year 1981
Number of shared co-authors 60

Collaborators

Martin E Gleave
University of British Columbia
Co-authored papers 61
Ladan Fazli
University of British Columbia
Co-authored papers 30
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 15
Alastair Davies
University of British Columbia
Co-authored papers 14
Yuzhuo Wang
University of British Columbia
Co-authored papers 12
Colin C Collins
University of British Columbia
Co-authored papers 11
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 11
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 10
Kim N Chi
University of British Columbia
Co-authored papers 9
Alexander W Wyatt
University of British Columbia
Co-authored papers 8
Dong Lin
Fujian Medical University Cancer Hospital and Fujian Cancer Hospital
Co-authored papers 8
Luke A Selth
Adelaide Medical School, University of Adelaide
Co-authored papers 8
Paul C Boutros
University of California los angeles
Co-authored papers 7
Mark A Rubin
University of Bern
Co-authored papers 6
Haiyang Guo
the Second Hospital, Cheeloo College of Medicine, Shandong University
Co-authored papers 5
Musaddeque Ahmed
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Elai Davicioni
Veracyte Inc.
Co-authored papers 5
Anne Haegert
University of British Columbia
Co-authored papers 5
Hui Xue
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Co-authored papers 5
Eric J Small
University of California san francisco
Co-authored papers 5
Junjie T Hua
School of Public Health, Sun Yat-sen University
Co-authored papers 5
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 4
Rahul Aggarwal
University of California San Francisco
Co-authored papers 4
Fraser Soares
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 4
David A Quigley
University of California-San Francisco
Co-authored papers 4
Wilbert Zwart
Oncode Institute, The Netherlands Cancer Institute
Co-authored papers 4
Christopher A Maher
Washington University in St Louis
Co-authored papers 4
Fan Mo
Institute of Stem Cell and Regeneration, Chinese Academy of Sciences
Co-authored papers 4
Yi Liang
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 4
Release 1.2